Novartis is struggling to win widespread coverage for its $2.1 million gene therapy for spinal muscular atrophy (SMA), Zolgensma, according to a FiercePharma report.
According to the report, only about a third of the top 30 insurers in the U.S. have made coverage decisions.
Bernstein analysts called the coverage decisions by 11 insurers to be “surprisingly restricted.”
“The restriction reflects unexpected and material payer resistance to the Zolgensma price point … ,” they wrote to clients.
To read the full report on FiercePharma, click here.